Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on Feb 10, 2021 5:39pm
118 Views
Post# 32532403

RE:RE:RE:RE:RE:Another PP is on the way

RE:RE:RE:RE:RE:Another PP is on the way

 


I hear you Actuarial , PMN and ATE have been my top two stocks base on share accumulation for the last 3/4 years, PMN bankrolled lots of things in my live in 2018 and I have a soft spot for it in my heart , it helped greatly with the accumulation on ATE too.. I'm still optimistic that things will turn for the better here, as much as management may have been inept , PMN has few other good things going on and not just focusing on PMN310 and Biogens , maybe is what the doctor order ... As I said before in the market right now you mention Covid and SP runs wild...I'm hopeful that sooner than later We will hear where We are with BCNI ..


Actuarial wrote: Mole101, I used to own over a million shares of PMN, and then I decided to drop all PMN and put my money into ATE right after PMN announced last PP. The science of PMN is amazingly great but the management team dumb. Under this management team, PMN couldn't have one thing completed but it still keep opening new battle fields. I still watch PMN but I am not going to put a penny into it until PMN get any real work done, or, they get a new competent management team.

Mole101 wrote:

Did you missed this Boat and like it lower Actuarial?.. I know We are looking good at ATE now ;).... startup Bioteches are on fire and you won't find anything under .25 , if it has the word Covid on their NRs ( saliva, ..)+.35s then... I think We are waking up and that 1.3 million traded south of the border maybe the wake up call. So, let's join .. if we're to have a PP , I will rather it's at .30 ..;)


quote=Actuarial]I mean what price do you think PP participant would like to pay? .12? .10? It could be only lower than last PP given PMN has no real developments. This reminds me the running up a few months ago when PMN announce the Covid story. Short lived pop is bubble, nothing else.


 



[/quote]
 

<< Previous
Bullboard Posts
Next >>